Table 4.

Drugs used in oncological therapy with known effects on cytochrome P450 and/or P-glycoprotein.

Type of Interaction	CYP3A4	P-Glycoprotein
Inducers (may increase DOAC plasma levels)	Cytostatics: paclitaxel, docetaxel, vincristine, vinorelbine Hormonal drugs: enzalutamide * Immunomodulators: dexamethasone, prednisone	Cytostatics: vinblastine, doxorubicin Tyrosine kinase inhibitors: vandetanib, sunitinib Immunomodulators: dexamethasone
Inhibitors (may reduce DOAC plasma levels)	Cytostatics: etoposide, doxorubicin, idarubicin, ifosfamide, cyclophosphamide, lomustine Tyrosine kinase inhibitors: imatinib, crizotinib, nilotinib, lapatinib, dasatinib Hormonal drugs: abiraterone, anastrozole Immunomodulators: cyclosporine, tacrolimus, temsirolimus	Tyrosine kinase inhibitors: imatinib, crizotinib, nilotinib, lapatinib Hormonal drugs: abiraterone, enzalutamide, tamoxifen Immunomodulators: cyclosporine, tacrolimus
Other substrates for CYP3A4 or/and P-glycoprotein	Cytostatics: vinblastine, irinotecan, busulfan Tyrosine kinase inhibitors: vemurafenib, vandetanib, sunitinib, erlotinib, gefitinib Monoclonal antibodies: brentuximab Hormonal drugs: bicalutamide, tamoxifen, flutamide, letrozole, fulvestrant Immunomodulators: everolimus	Cytostatics: paclitaxel, docetaxel, vincristine, vinorelbine, methotrexate, irinotecan, etoposide, daunorubicin, bendamustine

Adapted from Steffel et al., 2018 [37]; * especially strong interactions are printed in bold type.